Jing Ding

Title: Innovations by Jing Ding in Monoclonal Antibody Development

Introduction

Jing Ding is an accomplished inventor based in Changchun, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies for diagnostic purposes. His work focuses on addressing the technical challenges associated with diagnosing trichinellosis.

Latest Patents

Jing Ding holds a patent for a hybridoma cell strain and the monoclonal antibody produced therefrom against serine protease of intestinal stage. This invention aims to provide a specific diagnostic method for trichinellosis. The hybridoma cell strain is deposited under the accession number CGMCC No. 18317. The monoclonal antibody, Ts-ZH68-2A4-Ab, has shown the ability to compete with positive serum from infected pigs for binding to the Ts-ZH68 antigen. The recognition peptide identified in this process is GVDRSATCQGDSGGP. This innovation lays the groundwork for developing reagents or vaccines for diagnosing or preventing infections.

Career Highlights

Jing Ding is affiliated with Jilin University, where he continues to advance research in the field of immunology. His work has garnered attention for its potential applications in public health and disease prevention.

Collaborations

Jing Ding collaborates with notable colleagues, including Mingyuan Liu and Xiaolei Liu, who contribute to his research endeavors.

Conclusion

Jing Ding's innovative work in developing monoclonal antibodies represents a significant advancement in the field of diagnostics. His contributions are vital for improving methods of disease detection and prevention.